|Last Price$81.51||Day Change (%)-0.09%|
|Open Price$81.59||Day Change ($)-0.08|
|Day Range81.00–81.72||52-Week Range67.88–92.85|
As of Mon 7/25/2016 2:50:00 PM | USD
Fitch Affirms Eli Lilly's IDR at 'A'; Outlook Stable
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Review, H1 2016 Featuring AskAt, Eisai, Eli Lilly and Company, Kaken Pharmaceutical & Ono Pharmaceutical - Research and Markets
Global Bladder Cancer Therapeutics & Diagnostics Market - Expected to Grow 3-5% by 2020 - Research and Markets
Global Psoriasis Market Growth of 7.26% by 2024 - Analysis, Technologies & Forecasts Report 2016-2024 - Key Vendors: Johnson & Johnson, Novartis, Pfizer - Research and Markets
Global Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Pipeline Review 2016 - Research and Markets
Global Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Sanofi, Novartis, Bayer - Research and Markets
PureTech Appoints Feng Zhang to Scientific Advisory Board and Expands Team and Advisory Group
Dendrimers and Polymer Drug Conjugates Market (2016 - 2026) - 40 Polymer Drug Conjugates in Clinical Development - Research and Markets
These Gold-rated funds have Morningstar Sustainability Ratings of High despite not explicitly trying to do so.
The SEC recently charged Eli Lilly for violations of the FCPA and barred an Arizona-based fund manager from the industry after the fund’s collapse. FINRA ordered Pruco Securities to pay $10.7 million.